Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
27.08
+0.74 (2.81%)
Sep 11, 2024, 4:00 PM EDT - Market closed
Denali Therapeutics Employees
Denali Therapeutics had 445 employees as of December 31, 2023. The number of employees increased by 18 or 4.22% compared to the previous year.
Employees
445
Change (1Y)
18
Growth (1Y)
4.22%
Revenue / Employee
$2,847
Profits / Employee
-$943,043
Market Cap
3.88B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Surgery Partners | 13,500 |
Perrigo Company | 9,140 |
Evolent Health | 4,700 |
Haemonetics | 3,657 |
Axonics | 797 |
ADMA Biologics | 624 |
Prestige Consumer Healthcare | 570 |
Amicus Therapeutics | 517 |
DNLI News
- 8 days ago - Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) - GlobeNewsWire
- 22 days ago - Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology - Seeking Alpha
- 4 weeks ago - Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration - GlobeNewsWire
- 5 weeks ago - Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies - GlobeNewsWire
- 4 months ago - Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data - Seeking Alpha
- 4 months ago - Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 4 months ago - Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - GlobeNewsWire